Firdapse: first treatment for Lambert-Eaton myasthenic syndrome

Firdapse (amifampridine) is the first drug to be approved for the treatment of Lambert-Eaton myasthenic syndrome.

Amifampridine improves muscle strength and increases resting compound muscle action potential through blockade of voltage-dependent potassium channels, which results in increased intracellular calcium concentrations and leads ultimately to enhanced neuromuscular transmission.

Treatment is given on a daily basis in 3 or 4 divided doses and should be initiated under the supervision of a physician experienced in the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Because of the rarity of the condition data on amifampridine are limited and the product information will therefore be reviewed annually by the European Medicines Agency.

View Firdapse drug record

Further information: BioMarin Europe

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

MHRA restricts indications for quinolone antibiotics following EU-wide safety review

MHRA restricts indications for quinolone antibiotics following EU-wide safety review

New restrictions and precautions for use have been...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Anti-Anginal Preparations, Summary by Pharmacological Class

Anti-Anginal Preparations, Summary by Pharmacological Class

Available formulations of anti-anginal drugs.